# US 2026/0085362 A1 · Neuroendocrine carcinoma detection and treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085362 A1
- Document ID: US20260085362A1
- Status: Published application
- Kind: A1
- Application number: 19/335,755
- Filed: 2025-09-22
- Published: 2026-03-26
- Earliest claimed: 2024-09-20
- Assignees: Case Western Reserve University
- Applicants: Case Western Reserve University
- Inventors: Minh Lam; Afshin Dowlati; Hung-Ying Kao; Masaru Miyagi
- Web page: https://patentgrep.com/patent/US20260085362A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6851: Quantitative amplification
- G01N 21/6458: {Fluorescence microscopy (fluorescence microscopes per se G02B21/0076 and G02B21/16)}
- G01N 33/5752: of the lungs
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates generally to the field of medical oncology and, in particular, to methods and kits for identifying and treating neuroendocrine carcinomas, such as small cell neuroendocrine (SCN) tumors. Certain aspects of the present disclosure can include methods of diagnosing a patient with a neuroendocrine carcinoma, methods of determining a survival prognosis in a patient diagnosed with a neuroendocrine carcinoma, compositions that effectively inhibits or decreases an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in vivo or ex vivo, and methods of treating a patient having, or suspected of having, a neuroendocrine carcinoma.

## Claims

### Claim 1

A method of diagnosing a patient with a neuroendocrine carcinoma, comprising assaying for an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in a biological sample previously obtained from the patient, wherein a detected expression level of the HEPACAM2 biomarker that is higher than a control level of a HEPACAM2 biomarker is indicative of a neuroendocrine carcinoma in the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neuroendocrine carcinoma is small cell lung carcinoma (SCLC).

### Claim 3 (depends on 2)

The method of claim 2, wherein the SCLC is early-stage SCLC.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient is a member of a high-risk population for SCLC and is free of metastases.

### Claim 5 (depends on 3)

The method of claim 3, wherein the patient does not exhibit a high expression level of DLL3, SEZ6 and/or TROP2 as compared to a control expression level of DLL3, SEZ6 and/or TROP2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the expression level of a HEPACAM2 biomarker is expression of a HEPACAM2 mRNA and the expression level of a HEPACAM2 biomarker is a HEPACAM2 protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the HEPACAM2 protein is expressed and localized at a surface of a neuroendocrine carcinoma cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the assay is performed on one or more extravesicles secreted by a cell comprising a neuroendocrine carcinoma cell or a cell suspected of comprising a neuroendocrine carcinoma cell.

### Claim 9 (depends on 6)

The method of claim 6, wherein qPCR is used to assay the expression level of the HEPACAM2 mRNA and immunofluorescence microscopy or a biotin-pulldown technique is used to assay the expression level of the HEPACAM2 protein.

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering a therapeutically effective amount of a therapeutic regimen to a patient diagnosed with a neuroendocrine carcinoma, the therapeutic regimen being a therapy selected from the group consisting of chemotherapy, targeted therapy, radiation therapy, immunotherapy, surgery, and combinations thereof.

### Claim 11 (depends on 10)

The method claim 10, wherein the therapeutic regimen is administered subsequent to the beginning of a relapse episode.

### Claim 12

A method of determining a survival prognosis in a patient diagnosed with a neuroendocrine carcinoma, the method comprising:
assaying an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in a biological sample previously obtained from the patient; and
calculating a survival prognosis, based on the assayed expression level of the HEPACAM2 biomarker, comprising an overall survival (OS) and/or a progression-free survival (PFS);
wherein a detected expression level of the HEPACAM2 biomarker that is higher than a control level of a HEPACAM2 biomarker is indicative of a lesser OS and/or a lesser PFS as compared to a control patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the neuroendocrine carcinoma is small cell lung carcinoma (SCLC) and the patient is diagnosed with Stage 0, Stage I, Stage II, Stage III, or Stage IV SCLC, based on the TNM staging system.

### Claim 14

A method of treating a patient having, or suspected of having, a neuroendocrine carcinoma, the method comprising administering a therapeutically effective amount of a therapeutic regimen to the patient, wherein the neuroendocrine carcinoma is characterized by an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker that is higher than a control level of a HEPACAM2 biomarker.

### Claim 15 (depends on 14)

The method of claim 14, wherein the therapeutic regimen is a therapy selected from the group consisting of chemotherapy, targeted therapy, radiation therapy, immunotherapy, surgery, and combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the targeted therapy comprises an antibody-drug conjugate or a RNA interfering modality.

### Claim 17 (depends on 15)

The method of claim 15, wherein the immunotherapy comprises a CAR-T cell therapy.

### Claim 18 (depends on 14)

The method claim 14, wherein the therapeutic regimen is administered subsequent to the beginning of a relapse episode.

### Claim 19 (depends on 14)

The method of claim 14, wherein the neuroendocrine carcinoma is small cell lung carcinoma (SCLC) and the patient is diagnosed with Stage 0, Stage I, Stage II, Stage III, or Stage IV SCLC, based on the TNM staging system.
